Compounds and methods for the inhibition of the expression of VCAM-1 Number:7,189,870 from the United States Patent and Trademark Office (PTO) owispatent This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.<H expression, inhibition, Compounds, and, m, 7189870.html, Patent, pto, 7189870

Title: Compounds and methods for the inhibition of the expression of VCAM-1

Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

Patent Number: 7,189,870 Issued on 03/13/2007 to Somers

Inventors: Somers; Patricia K. (Atlanta, GA)
Assignee: AtheroGenic, Inc. (Alpharetta, GA)

Appl. No.: 10/647,766

Filed: August 25, 2003

Related U.S. Patent Documents


Application Number	Filing Date	Patent Number	Issue Date
10060734	Jan., 2002	6617352
09370046	Aug., 1999	6548699
09079213	May., 1998	6147250
60047020	May., 1997

Current U.S. Class: 560/9 ; 560/142

Current International Class: C07C 321/00 (20060101); C07C 69/00 (20060101)

Field of Search: 560/142,9

References Cited [Referenced By]

U.S. Patent Documents


3179701	April 1965	Rocklin
3479407	November 1969	Laufer
3576883	April 1971	Neuworth
3952064	April 1976	Whalley
4029812	June 1977	Wagner
4076841	February 1978	Wagner
4078084	March 1978	Wagner
4115590	September 1978	Lerner
4752616	June 1988	Hall
4755524	July 1988	Mueller et al.
4954514	September 1990	Kita
4968710	November 1990	Rustad
4975467	December 1990	Ku et al.
5043330	August 1991	Nguyen et al.
5061734	October 1991	Mao et al.
5066822	November 1991	Rustad et al.
5084214	January 1992	Kita et al.
5112870	May 1992	Mao et al.
5155250	October 1992	Parker
5206247	April 1993	Regnier
5262439	November 1993	Parthasarathy
5294724	March 1994	Jendralla et al.
5310949	May 1994	Dufresne et al.
5380747	January 1995	Medford
5411741	May 1995	Zaias
5512595	April 1996	Regnier et al.
5608095	March 1997	Parker
5627205	May 1997	Regnier et al.
5693337	December 1997	Suzuki et al.
5739374	April 1998	Janssen et al.
5750351	May 1998	Medford
5773209	June 1998	Medford et al.
5773231	June 1998	Medford et al.
5783596	July 1998	Medford et al.
5792787	August 1998	Medford et al.
5807884	September 1998	Medford et al.
5811449	September 1998	Medford et al.
5821260	October 1998	Medford et al.
5846959	December 1998	Medford et al.
6037377	March 2000	Anderskewitz et al.
6121319	September 2000	Somers
6147250	November 2000	Somers
6323359	November 2001	Jass
6548699	April 2003	Somers
6602914	August 2003	Meng
6617352	September 2003	Somers
6670398	December 2003	Edwards et al.
2002/0188118	December 2002	Meng
2002/0193446	December 2002	Meng
2003/0064967	April 2003	Luchoomun et al.

Foreign Patent Documents


27 16 125	Oct., 1977	DE
0190682	Aug., 1986	EP
0254272	Jan., 1988	EP
0292660	Nov., 1988	EP
0317165	May., 1989	EP
0348203	Dec., 1989	EP
0405788	Jan., 1991	EP
0418648	Mar., 1991	EP
0621255	Oct., 1994	EP
0763527	Mar., 1997	EP
0866049	Sep., 1998	EP
2130975	Nov., 1972	FR
2133024	Nov., 1972	FR
2134810	Dec., 1972	FR
2140769	Jan., 1973	FR
2140771	Jan., 1973	FR
2168137	Aug., 1973	FR
1136539	Dec., 1968	GB
1148550	Apr., 1969	GB
1199871	Jul., 1970	GB
49-075552	Jul., 1974	JP
06-312978	Nov., 1994	JP
73-28425	Dec., 1995	JP
09-059258	Mar., 1997	JP
WO 93/02051	Feb., 1993	WO
WO 94/07869	Apr., 1994	WO
WO 95/09158	Apr., 1995	WO
WO 95/15760	Jun., 1995	WO
WO 95/17408	Jun., 1995	WO
WO 95/30415	Nov., 1995	WO
WO 96/12703	May., 1996	WO
WO 97/15546	May., 1997	WO
WO 97/26258	Jul., 1997	WO
WO 97/48694	Dec., 1997	WO
WO 98/22418	May., 1998	WO
WO 99/24400	May., 1998	WO
WO 98/51289	Nov., 1998	WO
WO 98/51662	Nov., 1998	WO
WO 99/15159	Apr., 1999	WO
WO 00/26167	May., 2000	WO
WO 00/26184	May., 2000	WO
WO 00/28332	May., 2000	WO
WO 00/31053	Jun., 2000	WO
WO 00/59509	Oct., 2000	WO
WO 01/70757	Sep., 2001	WO
WO 01/70757	Sep., 2001	WO
WO 01/79164	Oct., 2001	WO
WO 01/79164	Oct., 2001	WO

Other References

Anonymous, "AtheroGenics announces positive Phase II results from CART-1 Clinical Trial for restenosis," (Press Release Nov. 12, 2001). cited by other .
Anonymous, "AtheroGenics: Faster than anticipated," BioCentury Extra (The Bernstein Report of Biobusiness), Reprint from May 29, 2001. cited by oth- er .
Barnhart, J.W., et al., Chapter 10: The Synthesis, metabolism, and biological activity of probucol and its analogs, Pharmacochem. Libr., 1991(17):277-299 (1991). XP002095165. cited by other .
Baron, J.L., et al., "The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between .alpha.-4-integrins and vascular cell adhesion molecule-1", J. Clin. Invest. 93:1700-1708 (Apr. 1994). cit- ed by other .
Brown, et al., "Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis", Ann. Rev. Biochem., 52:223-261 (1983). cited by other .
Burkly, L.C., et al., "Protection against adoptive transfer of autoimmune diabletes mediated through very late antigen-4 integrin", Diabetes, 43:529-534 (Apr. 1994). cited by other .
Carew, et al., "Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit", Proc. Natl. Acad. Sci. U.S.A., 84:7725-7729 (Nov. 1987). cited by other .
Cominacini, L., et al., Free Radical Biology and Medicine, 22(1/2):117-127 (1996) XP002095164. cited by other .
De Meglio, P., "New derivatives of clofibrate and probucol. Preliminary studies on hypolipemic activity," Il Farmaco, Ed. Sci. 40(11):833-844 (1985). With partial translation. Chem. Abstracts, 104(5):28675, (Feb. 3, 1986), XP 002124424. cited by other .
Feldman, D., et al., "The In Vitro and Ex Vivo Antioxidant Properties, and Hypolipidemic Activity of CGP 2881," Atherosclerosis, 144:343-355 (Dec. 28, 1998). cited by other .
Folkman, J., et al., "Angiogenesis", J. Biol. Chem., 267(16):10931-10934 (Jun. 5, 1992). cited by other .
Fruebis, J., "A Comparison of the Antiatherogenic Effects of Probucol and of a Structural Analogue of Probucol in Low Density Lipoprotein Receptor-deficient Rabbits," The American Society for Clinical Investigation, Inc., 94:392-398 (Jul. 1994). cited by other .
Gershbein et al., "Action of drugs and chemical agents on rat liver regeneration," Drug and Chemical Toxicology, 8(3):125-143 (1985). cited by other .
Heeg, et al., "Plasma levels of Procubol in man after single and repeated oral doses", La Nouvelle Presse Medicale, 9(40):2990-2994 (Oct. 30, 1980). Abstract in English. cited by other .
Iademarco, M.F., et al., "Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1)", J. Biol. Chem. 267(23):16323-16329 (Aug. 15, 1992). cited by other .
Kazuya et al., J. Lipid Res., 32:197-204 (1991). cited by other .
Kelarev, V.I., et al., Khim. Geterotsikl. Soedin, No. 5, pp. 667-673 (1995). Provided as Chem. Abstracts, AN 124:146082, XP002115604. cited by other .
Kelarev, V.I., et al., Khim. Geterotsikl. Soedin., No. 4, pp. 514-517 (1995). Provided as Chem. Abstracts AN 124(1):8690 (Jan. 1, 1996) XP002115603 and XP002115596. cited by other .
Koch, A.E., et al., "Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues", Lab. Invest., 64(3):313-320 (1991). cited by other .
Lankin, V.Z., et al., Dokl. Akad. Nauk., 351(4):554-557 (1996), Chem. Abstracts, AN 127(6):75973u (1997), XP002115597. cited by other .
Mamedov, Ch.I., et al., Mater. Nauchn. Konf. Aspir. Akad. Nauk Az. SSR, 1:127-131 (1980), Chem. Abstracts, AN 94:30290c (1981), XP002115600. cite- d by other .
Mao., S.J., et al., "Antioxidant Activity of Probucol and Its Analogues in Hypercholesterolemic watanabe Rabbits," Journal of Medicinal Chemistry, 34(1):298-302 (Jan. 1991). cited by other .
Mao, S.J., et al., "Attenuation of Atherosclerosis in a Modified Strain of Hypercholesterolemic Watanabe Rabbits with Use of a Probucol Analogues (MDL29,311) That Does Not Lower serum Cholesterol," Arteriosclerosis and Thrombosis. 11(5):1266-1275 (Sep.-Oct. 1991). cited by other .
Medvedev, A.I., et al., Tezisy Dokl. Nauchn. Sess. Khim. Tekhnol. Org. Soedin. Sery Sernistykh Neftei, 13.sup.th, pp. 123-124 (1974), Chem. Abstracts, AN 86(1):5066m (p. 437, Jan. 3, 1977). XP002115601, XP00215594. cited by other .
Miller, G.J., "High density lipoproteins and atherosclerosis", Ann. Rev. Med., 31:97-108 (1980). cited by other .
Morales-Ducret, J., et al., ".alpha.4/.beta.1 integrin (VLA-4) ligands in arthritis: vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes", J. Immunol., 149(4):1424-1431 (Aug. 15, 1992). cited by other .
Neuworth, M.B., "Synthesis and hypocholesterolemic activity of alkylidenedithio bisphenols," J. Med. Chem., 13(4) 722-725 (1970), Chem. Abstracts AN 73:445047 (1970), XP002124423. cited by other .
Ohkawara, Y., et al., "In situ expression of the cell adhesion molecules in bronchail tissues from asthmatics with air flow limitation: In vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration", Am. J. Respir. Cell. Mol. Biol., 12:4-12 (1995). cited by other .
Orosz, C.G., et al., "Role of the endothelial adhesion molecule VCAM in murine cardiac allograft rejection", Immunol. Lett., 32:7-12 (1992). cite- d by other .
Parthasarathy, S., et al., "Probucol inhibits oxidative modification of low density lipoprotein", J. Clin. Invest., 77:641-644 (1986). cited by other .
Pastor, S.D., et al., Phosphorus and Sulfur, 37(3-4):117-123 (1988), Chemical Abstracts, AN 110(23):212254a (Jun. 5, 1989), XP0021156682. cite- d by other .
Patton, J.G., et al., "Monoclonal antibodies to human plasma low-density lipoproteins. II. Evaluation for use in radioimmunoassay for apolipoprotein B in patients with coronary artery disease", Clin. Chem., 29(11):1898-1903 (1983). cited by other .
Pilewski, J.M., et al., "Cell adhesion molecules in asthma: homing, activation, and airway remodeling", J. Respir. Cell. Mol. Biol., 12:1-3 (1995). cited by other .
Rabb, H.A., et al., "The role of the leukocyte adhesion molecules VLA-4, LFA-1 and Mac-1 in allergic airway responses in the rat", Am. J. Respir. Crit. Care Med., 149:1186-1191 (1994). cited by other .
Ramasamy, S., et al., "Modulation of Expression on Edothelial Nitric Oxide Synthase by Nordihydroguaiaretic Acid, a Phenolic Antioxidant in Cultured Endothelial Cells," Molecular Pharmacology, 56(1):116-123 (Apr. 5, 1999). cited by other .
Rinninger, et al. , "Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism", Atherioschler. Throm. Vasc. Biol., 19:1325-1332 (1999). XP-008001008. cited by other .
Roberts, C.P., et al., "Regulation of Monocyte Macrophage Differentiation by Antiglucocorticods and Antioxidants," American Journal of Obstetrics and Gynecology, 179(2); 354-64 (Aug. 1998). cited by other .
Sawayama, Y., et al., "Effects of Probucol and Pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia", Journal of the American College of Cardiology, 39(4):610-616 (2002). cited by other .
Steinberg, D., et al., "Modifications of low-density lipoprotein that increase its atherogenicity", N. Eng. J. Med., 220(14):915-924 (1989). cited by other .
Tomich et al., Chemical Abstracts, AN 127(6):75971s (1997). cited by other .
Wagner, Jr., et al., Chemical Abstracts, AN 82:86189w (1975). cited by oth- er .
Yang, X.-D., et al., "Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors", Proc. Natl. Acad. Sci. U.S.A., 90:10494-10498 (1993). cited by other.

Primary Examiner: Oh; Taylor Victor
Attorney, Agent or Firm: King & Spalding

Parent Case Text

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Ser. No. 10/060,734 filed on Jan. 30, 2002, now U.S. Pat. No. 6,617,352, which is a continuation of U.S. Ser. No. 09/370,046, filed on Aug. 6, 1999, now U.S. Pat. No. 6,548,699, which is a continuation of U.S. Ser. No. 09/079,213 filed on May 14, 1998, now U.S. Pat. No. 6,147,250, which claims priority to U.S. provisional application Ser. No. 60/047,020 filed on May 14, 1997, the disclosures of which are incorporated herein by reference.

Claims

I claim:

1. A process for the preparation of an ester of probucol, comprising reacting: (i) reacting probucol with sodium hydride to generate a probucol phenoxide ion; and (ii) reacting the probucol phenoxide ion with an acid chloride or an acid anhydride to form the ester of probucol.

2. The process of claim 1, wherein the acid anhydride is succinic anhydride.

3. The process of claim 1, wherein approximately two equivalents of sodium hydride to one equivalent of probucol are used to generate the probucol phenoxide ion.

4. The process of claim 1, wherein approximately three equivalents of the acid chloride or acid anhydride are used to form the ester of probucol.

5. The process of claim 1, further comprising quenching the ester of probucol with aqueous HCl.

6. The process of claim 1, wherein the step (i) and (ii) are carried out in a solvent selected from the group consisting of DMF or THF.

7. The process of claim 1, wherein the acid anhydride is glutaric anhydride.

Description

FIELD OF THE INVENTION

This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

BACKGROUND OF THE INVENTION

Coronary heart disease (CHD) remains the leading cause of death in the industrialized countries. The primary cause of CHD is atherosclerosis, a disease characterized by the deposition of lipids in the arterial vessel wall, resulting in a narrowing of the vessel passages and ultimately hardening the vascular system.

Atherosclerosis as manifested in its major clinical complication, ischemic heart disease, continues to be a major cause of death in industrialized countries. It is now well accepted that atherosclerosis can begin with local injury to the arterial endothelium followed by proliferation of arterial smooth muscle cells from the medial layer to the intimal layer along the deposition of lipid and accumulation of foam cells in the lesion. As the atherosclerotic plaque develops it progressively occludes more and more of the affected blood vessel and can eventually lead to ischemia or infarction. Therefore, it is desirable to provide methods of inhibiting the progression of atherosclerosis in patients in need thereof.

Cardiovascular disease has been linked to several causative factors, which include hypercholesterolemia, hyperlipidemia, and the expression of VCAM-1 in vascular endothelial cells.

Expression of VCAM-1

Adhesion of leukocytes lo the endothelium represents a fundamental, early event in a wide variety of inflammatory conditions, including atherosclerosis, autoimmune disorders and bacterial and viral infections. Leukocyte recruitment to the endothelium is started when inducible adhesion molecule receptors on the surface of endothelial cells interact with counterreceptors on immune cells. Vascular endothelial cells determine which type of leukocytes (monocytes, lymphocytes, or neutrophils) are recruited, by selectively expressing specific adhesion molecules, such as vascular cell adhesion molecule-1 (CAM-1), intracellular adhesion molecule-1 (ICAM-1), and E-selectin. In the earliest stage of the atherosclerotic lesion, there is a localized endothelial expression of VCAM-1 and selective recruitment of mononuclear leukocytes that express the integrin counterreceptor VLA-4. Because of the selective expression of VLA-4 on monocytes and lymphocytes, but not neutrophils, VCAM-1 is important in mediating the selective adhesion of mononuclear leukocytes. Subsequent conversion of leucocytes to foamy macrophages results in the synthesis of a wide variety of inflammatory cytokines, growth factors, and chemoattractants that help propagate the leukocyte and platelet recruitment, smooth muscle cell proliferation, endothelial cell activation, and extracellular matrix synthesis characteristic of maturing atherosclerotic plaque.

VCAM-1 is a mediator in chronic inflammatory disorders such as asthma, rheumatoid arthritis and autoimmune diabetes. For example, it is known that the expression of VCAM-1 and ICAM-1 are increased in asthmatics. Pilewski, J. M., et al. Am. J. Respir. Cell Mol. Biol. 12, 1 3 (1995); Ohkawara, Y., et al., Am. J. Respir. Cell Mol. Biol. 12, 4 12 (1995). Additionally, blocking the integrin receptors for VCAM-1 and ICAM-1 (VLA-4 and LFA-1, respectively) suppressed both early and late phase responses in an ovalbumin-sensitized rat model of allergic airway responses. Rabb, 11. A., et al., Am. J. Respir. Care Med. 149, 1186 1191 (1994). There is also increased expression of endothelial adhesion molecules, including VCAM-1, in the microvasculature of rheumatoid synovium. Koch, A. E. et al., Lab. Invest. 64, 313 322 (1991); Morales-Ducret, J. et al., Immunol. 149, 1421 1431 (1992). Neutralizing antibodies directed against VCAM-1 or its counter receptor, VLA-4, can delay the onset of diabetes in a mouse model (NOD mice) which spontaneously develop the disease. Yang, X. D. et al., Proc. Natl. Acad. Sci. U.S.A. 90, 10494 10498 (1993); Burkly, L. C. et al., Diabetes 43, 523 534 (1994); Baron, J. L. et al., J. Clin. Invest. 93, 1700 1708 (1994). Monoclonal antibodies to VCAM-1 can also have a beneficial effect in animal models of allograft rejection, suggesting that inhibitors of VCAM-1 expression may have utility in preventing transplant rejection. Oroez, C. G. et al., Immunol. Lett. 32, 7 12 (1992).

VCAM-1 is expressed by cells both as a membrane bound form and as a soluble form. The soluble form of VCAM-1 has been shown to induce chemotaxis of vascular endothelial cells in vitro and stimulate an angiogenic response in rat cornea. Koch, A. F. et al., Nature 376, 517 519 (1995). Inhibitors of the expression of soluble VCAM-1 have potential therapeutic value in treating diseases with a strong angiogenic component, including tumor growth and metastasis. Folkman, J., and Shing, Y., Biol. Chem. 10931 10934 (1992).

VCAM-1 is expressed in cultured human vascular endothelial cells after activation by lipopolysaccharide (LPS) and cytokines such as interleukin-1 (IL-1) and tumor necrosis factor (TNF-.alpha.). These factors are not selective for activation of cell adhesion molecule expression.

U.S. Pat. No. 5,380,747 to Medford, et al., teaches the use of dithiocarbamates such as pyrrolidine dithiocarbamate for the treatment of cardiovascular and other inflammatory diseases.

U. S. Pat. No. 5,750,351 to Medford, et al., and WO95/30415 to Emory University describe the discovery that polyunsaturated fatty acids ("PUFAs") and their hydroperoxides ("ox-PUFAs"), which are important components of oxidatively modified low density lipoprotein (LDL), induce the expression of VCAM-1, but not intracellular adhesion molecule-1 (ICAM-1) or E-selectin in human aortic endothelial cells, through a mechanism that is not mediated by cytokines or other noncytokine signals. This is a fundamental discovery of an important and previously unknown biological pathway in VCAM-1 mediated immune responses.

As non-limiting examples, linoleic acid, linolenic acid, arachidonic acid, linoleyl hydroperoxide (13-HPODE) and arachidonic hydroperoxide (15-HPETE) induce cell-surface gene expression of VCAM-1 but not ICAM-1 or E-selectin. Saturated fatty acids (such as stearic acid) and monounsaturated fatty acids (such as oleic acid) do not induce the expression of VCAM-1, ICAM-1 or E-selectin.

The induction of VCAM-1 by PUFAs and their fatty acid hydroperoxides is suppressed by dithiocarbamates, including pyrrolidine dithiocarbamate (PDTC). This indicates that the induction is mediated by an oxidized signal molecule, and that the induction is prevented when the oxidation of the molecule is blocked (i.e., the oxidation does not occur), reversed (i.e., the signal molecule is reduced), or when the redox modified signal is otherwise prevented from interacting with its regulatory target.

Cells that are chronically exposed to higher than normal levels of polyunsaturated fatty acids or their oxidized counterparts can initiate an immune response that is not normal and which is out of proportion to the threat presented, leading to a diseased state. The oversensitization of vascular endothelial cells to PUFAs and ox-PUFAs can accelerate the formation, for example, of atherosclerotic plaque.

Based on these discoveries, a method for the treatment of atherosclerosis, post-angioplasty restenosis, coronary artery diseases, angina, small artery disease and other cardiovascular diseases, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1, was described in WO95/30415 that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids including but not limited to oxidized linoleic (C.sub.18.DELTA..sup.9,12), linolenic (C.sub.18.DELTA..sup.6,9,12), arachidonic (C.sub.20.DELTA..sup.5,8,11,14) and eicosatrienoic (C.sub.20.DELTA..sup.8,11,14) acids.

Nonlimiting examples of noncardiovascular inflammatory diseases that are mediated by VCAM-1 include rheumatoid and osteoarthritis, asthma, dermatitis, and multiple sclerosis.

Hypercholesterolemia and Hyperlipidemia

Hypercholesterolemia is an important risk factor associated with cardiovascular disease. Serum lipoproteins are the carriers for lipids in the circulation. Lipoproteins are classified according to their density chylomicrons, very low-density lipoproteins (VLDL), low density lipoproteins (LDL) and high-density lipoproteins (HDL). Chylomicrons primarily participate in transporting dietary triglycerides and cholesterol from the intestine to adipose tissue and liver. VLDL deliver endogenously synthesized triglycerides from liver to adipose and other tissues. LDL transports cholesterol to peripheral tissues and regulate endogenous cholesterol levels in those tissues. HDL transports cholesterol from peripheral tissues to the liver. Arterial wall cholesterol is derived almost exclusively from LDL. Brown and Goldstein, Ann. Rev. Biochem. 52, 223 (1983); Miller, Ann. Rev. Med. 31, 97 (1980). In patients with low levels of LDL, the development of atherosclerosis is rare.

Steinberg, et al., (N. Eng. J. Med. 1989; 320:915 924) hypothesized that modification of low-density lipoprotein (LDL) into oxidatively modified LDL (ox-LDL) by reactive oxygen species is the central event that initiates and propagates atherosclerosis. Oxidized LDL is a complex structure consisting of at least several chemically distinct oxidized materials, each of which, alone or in combination, may modulate cytokine-activated adhesion molecule gene expression. R fatty acid hydroperoxides such as linoleyl hydroperoxide (13-HPODE) are produced from free fatty acids by lipoxygenases and are an important component of oxidized LDL.

It has been proposed that a generation of oxidized lipids is formed by the action of the cell lipoxygenase system and that the oxidized lipids are subsequently transferred to LDL. There is thereafter a propagation reaction within the LDL in the medium catalyzed by transition metals and/or sulfhydryl compounds. Previous investigations have demonstrated that fatty acid modification of cultured endothelial cells can alter their susceptibility to oxidant injury, whereas supplementation with polyunsaturated fatty acids (PUFA) enhances susceptibility to oxidant injury. Supplementation of saturated or monounsaturated fatty acids to cultured endothelial cells reduces their susceptibility to oxidant injury, whereas supplementation with polyunsaturated fatty acids (PUFA) enhances susceptibility to oxidant injury.

Using reverse-phase HPLC analysis of native and saponified liquid extracts of LDL, it has been demonstrated that 13-HPODE is the predominant oxidized fatty acid in LDL oxidized by activated human monocytes. Chronic exposure to oxidized LDL provides an oxidative signal to vascular endothelial cells, possible through a specific fatty acid hydroperoxide, that selectively augments cytokine-induced VCAM-1 gene expression.

Through a mechanism that is not well defined, areas of vessel wall predisposed to atherosclerosis preferentially sequester circulating LDL. Through a poorly understood pathway, endothelial, smooth muscle, and/or inflammatory cells then convert LDL to ox-LDL. In contrast to LDL, which is taken up through the LDL receptor, monocytes avidly take up ox-LDL through a "scavenger" receptor whose expression, unlike the LDL receptor, is not inhibited as the content of intracellular lipid rises. Thus, monocytes continue to take up ox-LDL and become lipid-engorged macrophage-foam cells that form the fatty streak.

There is now a large body of evidence demonstrating that hypercholesterolemia is an important risk factor associated with heart disease. For example, in December 1984, a National Institute of Health Consensus Development Conference Panel concluded that lowering definitely elevated blood cholesterol levels (specifically blood levels of low-density lipoprotein cholesterol) will reduce the risk of heart attacks due to coronary heart disease.

Typically, cholesterol is carried in the blood of warm-blooded animals in certain lipid-protein complexes such as chylomicrons, very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL). It is widely accepted that LDL functions in a way that directly results in deposition of the LDL cholesterol in the blood-vessel wall and that HDL functions in way that results in the HDL picking up cholesterol from the vessel wall and transporting it to the liver where it is metabolized [Brown and Goldstein, Ann. Rev. Biochem. 52, 223 (1983); Miller, Ann. Rev. Med. 31, 97 (1980)]. For example, in various epidemiologic studies the LDL cholesterol levels correlate well with the risk of coronary heart disease whereas the HDL cholesterol levels are inversely associated with coronary heart disease [Patton et al., Clin. Chem. 29, 1980 (1983)]. It is generally accepted by those skilled in the art that reduction of abnormally high LDL cholesterol levels is effective therapy not only in the treatment of hypercholesterolemia but also in the treatment of atherosclerosis.

Furthermore, there is evidence based on animal and laboratory findings that peroxidation of LDL lipid, such as the unsaturated fatty acid portions of LDL cholesteryl esters and phospholipids, facilitate the accumulation of cholesterol in monocyte/macrophages which eventually are transformed into foam cells and become deposited in the sub-endothelial space of the vessel wall. The accumulation of foam cells in the vessel wall is recognized as an early event in the formation of an atherosclerotic plaque. Thus it is believed that peroxidation of LDL lipid is an important prerequisite to the facilitated accumulation of cholesterol in the vessel wall and the subsequent formation of an atherosclerotic plaque. For example, it has been shown that monocyte/macrophages take up and degrade native LDL at relatively low rates and without marked accumulation of cholesterol. In contrast, oxidized LDL is taken up by these monocyte/macrophages at much higher rates and with marked accumulation of cholesterol [Parthasarathy et al., J. Clin. Invest 77, 641 (1986)]. It is therefore desirable to provide methods of inhibiting LDL lipid peroxidation in a patient in need thereof.

Elevated cholesterol levels are associated with a number of disease states, including restenosis, angina, cerebral atherosclerosis, and xanthoma. It is desirable to provide a method for reducing plasma cholesterol in patients with, or at risk of developing, restenosis, angina, cerebral arteriosclerosis, xanthoma, and other disease states associated with elevated cholesterol levels.

Since it has been determined that hypercholesterolemia is due to elevated LDL (hyperlipidemia), the lowering of LDL levels by dietary therapy is attempted. There are several drug classes that are commonly used to lower LDL levels, including bile acid sequestrants, nicotinic acid (niacin), and 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Probucol and the fibrate derivatives are sometimes used as adjunctive therapy, usually in combination with other medications. The HMG CoA reductase inhibitors have been termed statins or vastatins. Statins are among the most effective agents currently on the market for hypercholesterolemia, and include pravastatin (Pravchol, Bristol Myers Squibb), atorvastatin (Warner Lambert/Pfizer), simvastatin (Zocor, Merck), lovastatin (Mevacor, Merck), and fluvastatin (Lescol).

Evidence suggests that the atherogenic effects of low density lipoprotein (LDL) may be in part mediated through its oxidative modification. Probucol has been shown to possess potent antioxidant properties and to block oxidative modification of LDL. Consistent with these findings, probucol has been shown to actually slow the progression of atherosclerosis in LDL receptor-deficient rabbits as discussed in Carew et al. Proc. Natl. Acad. Sci. U.S.A. 84:7725 7729 (1987). Most likely, probucol is effective because it is highly lipid soluble and is transported by lipoproteins, thus protecting them against oxidative damage.

Probucol is chemically related to the widely used food additives 2,[3]-tert-butyl-4-hydroxyanisole (BHT) and 2,6-di-tert-butyl-4-methyl phenol (BHT). Its full chemical name is 4,4'-(isopropylidenedithio)bis(2,6-di-tert-butylphenol).

Probucol is used primarily to lower serumn cholesterol levels in hypercholesterolemic patients. Probucol is commonly administered in the form of tablets available under the trademark Lorelco.TM.. Unfortunately, probucol is almost insoluble in water and therefore cannot be injected intravenously. In fact, probucol is difficult for cells to absorb in vitro because of its poor miscibility in buffers and media for cell culture. Solid probucol is poorly absorbed into the blood, and is excreted in substantially unchanged form. Further, the tablet form of probucol is absorbed at significantly different rates and in different amounts by different patients. In one study (Heeg et al., Plasma Levels of Probucol in Man After Single and Repeated Oral Doses, La Nouvelle Presse Medicale, 9:2990 2994 (1980)), peak levels of probucol in sera were found to differ by as much as a factor of 20 from patient to patient. In another study, Kazuya et al. J. Lipid Res. 32; 197 204 (1991) observed an incorporation of less than about 1 .mu.g of probucol/10.sup.6 cells when endothelial cells are incubated for 24 h with 50 .mu.M probucol.

U.S. Pat. No. 5,262,439 to Parthasarathy discloses analogs of probucol with increased water solubility in which one or both of the hydroxyl groups are replaced with ester groups that increase the water solubility of the compound. In one embodiment, the derivative is selected from the group consisting of a mono- or di-probucol ester of succinic acid, glutaric acid, adipic acid, seberic acid, sebacic acid, azelaic acid, or maleic acid. In another embodiment, the probucol derivative is a mono- or di-ester in which the ester contains an alkyl or alkenyl group that contains a functionality selected from the group consisting of a carboxylic acid group, amine group, salt of an amine group, amide groups, amide groups, and aldehyde groups.

A series of French patents disclose that certain probucol derivatives are hypocholesterolemic and hypolipemic agents: Fr 2168137 (bis 4-hydroxyphenylthioalkane esters); Fr 2140771 (tetralinyl phenoxy alkanoic esters of probucol); Fr 2140769 (benzofuryloxyalkanoic acid derivatives of probucol); Fr 2134810 (bis-(3-alkyl-5-t-alkyl-4-thiazole-5-carboxy)phenylthio)alkanes; FR 2133024 (bis-(4-nicotinoyloxyphenylthio)propanes; and Fr 2130975 (bis(4-(phenoxyalkanoyloxy)-phenylthio)alkanes).

U.S. Pat. No. 5,155,250 to Parker, et al. discloses that 2,6-dialkyl4-silylphenols are antiatberosclerotic agents. The same compounds are disclosed as serum cholesterol lowering agents in PCT Publication No. WO 95/15760, published on Jun. 15, 1995. U.S. Pat. No. 5,608,095 to Parker, et al. discloses that alkylated-4-silyl-phenols inhibit the peroxidation of LDL, lower plasma cholesterol, and inhibit the expression of VCAM-1, and thus are useful in the treatment of atherosclerosis.

A series of European patent applications and to Shionogi Seiyaku Kabushiki Kaisha disclose phenolic thioethers for use in treating arteriosclerosis. European Patent Application No.348 203 discloses phenolic thioethers which inhibit the denaturation of LDL and the incorporation of LDL by macrophages. The compounds are useful as anti-arteriosclerosis agents. Hydroxamic acid derivatives of these compounds are disclosed in European Patent Application No. 405 788 and are useful for the treatment of arteriosclerosis, ulcer, inflammation and allergy. Carbamoyl and cyano derivatives of the phenolic thioethers are disclosed in U.S. Pat. No. 4,954,514 to Kita, et al.

U.S. Pat. No. 4,752,616 to Hall, et al., disclose arylthioalkylphenylcarboxylic acids for the treatment of thrombotic disease. The compounds disclosed are useful as platelet aggregation inhibitors for the treatment of coronary or cerebral thromboses and the inhibition of bronchoconstriction, among others.

A series of patents to Adir et Compagnie disclose substituted phenoxyisobutyric acids and esters useful as antioxidants and hypolipaemic agents. This series includes U.S. Pat. Nos. 5,206,247 and 5,627,205 to Regnier, et al. (which corresponds to European Patent Application No. 621 255) and European Patent Application No. 763 527.

WO97/15546 to Nippon Shinyaku Co. Ltd. discloses carboxylic acid derivatives for the treatment of arterial sclerosis, ischemic heart diseases, cerebral infarction and post PTCA restenosis.

The Dow Chemical Company is the assignee of patents to hypolipidemic 2-(3,5-di-tert-butyl-4-hydroxyphenyl)thio carboxamides. For example, U. S. Pat. Nos. 4,029,812, 4,076,841 and 4,078,084 to Wagner, et al., disclose these compounds for reducing blood serum lipids, especially cholesterol and triglyceride levels.

Given that cardiovascular disease is currently the leading cause of death in the United States, and ninety percent of cardiovascular disease is presently diagnosed as atherosclerosis, there is a strong need to identify new methods and pharmaceutical agents for its treatment. Important to this goal is the identification and manipulation of the specific oxidized biological compounds that act as selective regulators of the expression of mediators of the inflammatory process, and in particular, VCAM-1. A more general goal is to identify selective methods for suppressing the expression of redox sensitive genes or activating redox sensitive genes that are suppressed.

It is therefore an object of the present invention to provide new compounds, compositions and methods for the treatment of cardiovascular and inflammatory diseases.

It is still another object of the present invention to provide new compounds and compositions which are useful as inhibitors of LDL lipid peroxidation.

It is still another object of the present invention to provide new compounds and compositions which are useful as antiatherosclerotic agents.

It is still another object of the present invention to provide new compounds and compositions which are useful as LDL lipid lowering agents.

It is still another object of the present invention to provide new compounds, compositions and methods for selectively inhibiting the expression of VCAM-1.

It is still another object of the present invention to provide a method for the treatment of a disease that is mediated by the expression or suppression of a redox sensitive gene, for example MCP-1, IL-6 and thrombin receptor.

SUMMARY OF THE INVENTION

The present invention provides a compound, composition and method for inhibiting the expression of VCAM-1, and thus can be used in the treatment of a disease mediated by VCAM-1, which includes administering a compound of formula (I) or (II), or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier. The compounds of formula (I) are

##STR00001## wherein

X is O, S, SO, SO.sub.2, CH.sub.2, or NH;

Spacer is a group selected from the group consisting of --(CH.sub.2).sub.n--, --(CH.sub.2).sub.n--CO--, --(CH.sub.2).sub.n--N--, --(CH.sub.2).sub.n--O--, --(CH.sub.2).sub.n--S--, --(CH.sub.2O)--, --(OCH.sub.2)--, --(SCH.sub.2)--, --(CH.sub.2S--), -(aryl-O)--, --(O-aryl)-, -(alkyl-O)--, --(O-alkyl)-;

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

Y is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkoxyalkyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylthioalkyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfinylalkyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkylsulfonylalkyl, NH.sub.2, NHR, NR.sub.2, SO.sub.2--OH, OC(O)R, C(O)OH, C(O)OR, C(O)NH.sub.2, C(O)NHR, C(O)NR.sub.2, SO.sub.2NH.sub.2, SO.sub.2NHR, SO.sub.2NR.sub.2;

R is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkyl-COOH, alkyl-COOalkyl, alkyl-COOaryl, heteroaryl, substituted heteroaryl, or when attached to a nitrogen atom, two adjacent R groups may combine to form a ring of 5 to 7 members;

R.sup.1 and R.sup.2 are independently straight chained, branched, or cyclic alkyl which may be substituted, aryl, substituted aryl, heteroaryl, substituted beteroaryl, alkaryl, or aralkyl; and wherein substituents on the R.sup.1 or R.sup.2 groups are selected from the group consisting of hydrogen, halogen, alkyl, nitro, amino, alkylamino, dialkylamino, acyl, and acyloxy;

R.sup.3 and R.sup.4 are independently any group that does not otherwise adversely affect the desired properties of the molecule, including H, halogen, or R.sup.1.

The compound of formula (II) has the following structure

##STR00002## wherein

R.sub.a, R.sub.b, R.sub.c, and R.sub.d are independently any group that does not otherwise adversely affect the desired properties of the molecule, including hydrogen, straight chained, branched, or cyclic alkyl which may be substituted, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl, aralkyl or substituted aralkyl; substituents on the R.sub.a, R.sub.b, R.sub.c and R.sub.d groups are selected from the group consisting of hydrogen, halogen, alkyl, nitro, amino, haloalkyl, alkylamino, dialkylamino, acyl, and acyloxy;

Z is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, aralkyl, alkaryl, heteroaryl, heteroaralkyl, a carbohydrate group, --(CH.sub.2)--R.sub.c, --C(O)--R.sub.g, and --C(O)--(CH.sub.2).sub.n--R.sub.h, wherein (a) when each of R.sub.a, R.sub.b, R.sub.c, and R.sub.d are t-butyl, Z cannot be hydrogen and (b) when each of R.sub.a, R.sub.b, R.sub.c, and R.sub.d are t-butyl, Z cannot be the residue of succinic acid;

R.sub.c is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkyloxy, alkoxyalkyl, substituted alkoxyalkyl, NH.sub.2, NHR, NR.sub.2 mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyloxy, substituted acyloxy, COOH, COOR, --CH(OH)R.sub.k, hydroxy, C(O)NH.sub.2, C(O)NHR, C(O)NR.sub.2;

R.sub.g is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkyloxy, alkoxyalkyl, substituted alkoxyalkyl, NH.sub.2, NHR, NR.sub.2, mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;

R.sub.h is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkyloxy, alkoxyalkyl, substituted alkoxyalkyl, NH.sub.2, NHR, NR.sub.2, mono- or polyhydroxy-substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyloxy, substituted acyloxy, COOH, COOR, --CH(OH)R.sub.k, hydroxy, O-phosphate, C(O)NH.sub.2, C(O)NHR, C(O)NR.sub.2 and pharmaceutically acceptable salts thereof;

Or, in an alternative embodiment, R.sub.c, R.sub.g, and R.sub.h can independently be a substituent which improves the water solubility of the compound, including, but not limited to C(O)-spacer-SO.sub.3H, wherein spacer is as defined above, C(O)-spacer-SO.sub.3M, wherein M is a metal used to form a pharmaceutically acceptable salt, for example, sodium, C(O)-spacer-PO.sub.3H.sub.2, C(O)-spacer-PO.sub.3M.sub.2, C(O)-spacer-PO.sub.3HM, C(O)-spacer-PO.sub.4H, C(O)-spacer-PO.sub.4M, SO.sub.3M, --PO.sub.3H.sub.2, --PO.sub.3M.sub.2, --PO.sub.3HM, cyclic phosphates, polyhydroxyalkyl, carbohydrate groups, C(O)-spacer-[O(C.sub.1-3alkyl).sub.p].sub.n, wherein n is as defined above and p is 1, 2, or 3, --[O(C.sub.1-3alkyl).sub.p].sub.n, carboxy lower alkyl, lower alkylcarbonyl lower alkyl, N,N-dialkyl amino lower alkyl, pyridyl lower alkyl, imidazolyl lower alkyl, morpholinyl lower alkyl, pyrrolidinyl lower alkyl, thiazolinyl lower alkyl, piperidinyl lower alkyl, morpholinyl lower hydroxyalkyl, N-pyrryl, piperazinyl lower alkyl, N-alkyl piperazinyl lower alkyl, triazolyl lower alkyl, tetrazolyl lower alkyl, tetrazolylamino lower alkyl, or thiazolyl lower alkyl.

The present invention generally provides a method for treating cardiovascular and inflammatory disorders in a patient in need thereof comprising administering to said patient an effective amount of a compound of formula (I) or formula (II).

The present invention further provides a method of inhibiting the peroxidation of LDL lipid in a patient in need thereof comprising administering to said patient an effective antioxidant amount of a compound of formula (I) or formula (II).

In an alternative embodiment, a method is provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount to prevent the oxidation of the oxidized signal, and typically, the oxidation of a PUFA of a compound of formula (I) or formula (II). Representative redox-sensitive genes that are involved in the presentation of an immune response include, but are not limited to, those expressing c